Hemagen Diagnostics, Inc. (HMGN)
Hemagen Diagnostics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Columbia, MD, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $3,100. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -22.4%. Its beta of 0.36 implies it has historically moved less than the broad market.
Hemagen Diagnostics, Inc., a global biotechnology firm, specializes in delivering clinical diagnostic solutions for both human and animal health. The company designs, manufactures, and distributes the VIRGO product line, a series of human clinical immunoassays used for identifying autoimmune and infectious diseases, as well as acute phase proteins. Its comprehensive human diagnostic portfolio also encompasses Universal IFA components, various supplies, controls, calibrators, accessories, H-rotors, reagents, electrodes, equipment, and specialized assays covering conditions such as Chagas, acute phase proteins, and cytokines. For the veterinary market, Hemagen Diagnostics provides diagnostic equipment, reagents, consumables, accessories, and electrodes crucial for chemistry, hematology, and electrolyte analysis. The company reaches a diverse customer base, including laboratories, hospitals, and blood banks, through both direct sales and an extensive distribution network. Established in 1985, Hemagen Diagnostics maintains its headquarters in Columbia, Maryland.
Hemagen Diagnostics, Inc. is most often compared with the following Healthcare names: